Nautilus Biotechnology Inc. (NAUT)
NASDAQ: NAUTIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NAUT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $270.03M
- EPS (TTM)
- -$0.46
- Dividend yield
- None
- 52-week range
- 0.841 – 4.31
- Day range
- 1.91 – 2.17
- Volume / Avg
- 6.24M / 6.25M
- Beta
- —
- Shares outstanding
- 127.37M
52-week range
NAUT stock today
On Nov 20, NAUT ended the session at $2.12, shedding $0.05 (2.30%), versus the S&P 500's 3.70% decline. At this level, NAUT sits in the middle of its 52-week range of $0.841 to $4.31: 50.8% below the high, set on Mar 25, 2026 and 152.1% above the low. NAUT is up 8.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.4%.
Nautilus Biotechnology has posted a net loss over the last twelve months (EPS of -$0.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nautilus Biotechnology
Company profileNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. Sujal M. Patel
- Headquarters
- Seattle, WA
- Employees
- 128
- IPO year
- 2020
- Website
- nautilus.bio
Financial highlights
Full financialsNautilus Biotechnology reported a net loss of $59.0 million, compared with a loss of $70.8 million a year earlier. Diluted earnings per share came in at -$0.47.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-59.00M | $-70.78M | $-63.67M | $-57.92M | $-50.31M |
| EPS (diluted) | $-0.47 | $-0.56 | $-0.51 | $-0.46 | $-0.60 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$4.00+88.68%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $-0.11 vs $-0.14
- Surprise
- +21.43%
NAUT news
All NAUT news- Nautilus (NAUT) Q3 2026 Earnings Call TranscriptNasdaq
- Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS ConsortiumGlobeNewswire
- Nautilus Biotechnology Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026GlobeNewswire
Nautilus Biotechnology peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LABStandard BioTools Inc. | 0.631 | +2.82% | $249.11M | vs NAUT |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs NAUT |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs NAUT |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs NAUT |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs NAUT |
| PACBPacific Biosciences of California Inc. | 1.63 | -7.39% | $508.95M | vs NAUT |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs NAUT |
| EYPTEyePoint Inc. | 0.2342 | -11.36% | $26.65M | vs NAUT |
Indexes, lists and sector
Nautilus Biotechnology stock FAQ
What is Nautilus Biotechnology's stock price today?
NAUT last traded at $2.12 as of Nov 20, 4:00 PM EST, down 2.30% on the day. Prices are delayed at least 15 minutes.
Who is Nautilus Biotechnology's CEO?
Mr. Sujal M. Patel is the chief executive officer of Nautilus Biotechnology Inc., which has about 128 employees.
What is the NAUT 52-week high?
The 52-week high for NAUT is $4.31 and the 52-week low is $0.841. The stock is currently 50.8% below its high.